NEW HOPE, Pa.--(BUSINESS WIRE)--“Dr. Salemme is broadly recognized in the pharmaceutical industry as a business leader and entrepreneur with deep expertise in the application of crystallography and structure-based design to drug discovery and, more broadly, to molecular research. We are excited by the opportunity to benefit from Ray's experience and guidance at BioLeap in building a capital-efficient business leveraging our new techniques in moiety-based design of novel therapeutic compounds,” commented Dr. John Kulp, CEO of BioLeap. "I am delighted to have the opportunity to work with BioLeap. They have a great team that has developed a streamlined approach to structure-based drug design that can be leveraged to a variety of business models," commented Dr. Raymond Salemme.
